Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

This study tests a combination of two targeted drugs — pemigatinib (which blocks an abnormal growth signal called FGFR) and afatinib (which blocks another growth signal called EGFR/HER) — in people with advanced solid tumors that have stopped responding to standard treatments and have specific genetic changes in the FGFR gene. **You may be eligible if...** - You have an advanced or metastatic solid tumor (any cancer type) that cannot be surgically removed - Standard treatments are no longer working or are not appropriate for you - Your tumor has an FGFR1–3 fusion, rearrangement, activating mutation, or specific FGFR2 change confirmed by a certified lab test - You are in good general health (ECOG score 0–1) **You may NOT be eligible if...** - Standard treatments with a meaningful chance of benefit are still available and appropriate for you - You have serious eye, heart, liver, or lung conditions - You are pregnant or breastfeeding - You have received prior FGFR-targeted therapy that caused you to stop treatment due to toxicity Talk to your doctor to see if this trial is right for you.